Open AccessSynergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480
Author(s) -
LiHong Xu,
Changsheng Deng,
Yufan Zhu,
Shiquan Liu,
Dong-Zhou Liu
Publication year - 2003
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v9.i6.1241
Subject(s) - doxorubicin , apoptosis , cytotoxicity , flow cytometry , cell culture , mtt assay , microbiology and biotechnology , tumor necrosis factor alpha , cancer research , cancer cell , biology , in vitro , chemistry , immunology , cancer , chemotherapy , biochemistry , genetics
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) has been reported to specifically induce apoptosis of cancer cells although only a small percentage of cell lines were sensitive to it. Cell lines not responding to TRAIL in vitro were said to be more prone to apoptosis when TRAIL was combined with another anticancer agent. Generally, factors affecting drug-sensitivity involve many apoptosis-related proteins, including p53. The expression of wild-type p53 gene was proposed as an important premise for tumor cells responding to chemotherapy. The present study was to investigate the cell killing action of TRAIL on colon cancer cell line SW480, its synergistic effect with doxorubicin, and the possible mechanisms.